View Future GrowthGenic 과거 순이익 실적과거 기준 점검 4/6Genic은 연평균 67.9%의 비율로 수입이 증가해 온 반면, Personal Products 산업은 수입이 23.8% 증가했습니다. 매출은 연평균 19.9%의 비율로 증가했습니다. Genic의 자기자본이익률은 42.3%이고 순이익률은 21%입니다.핵심 정보67.86%순이익 성장률66.14%주당순이익(EPS) 성장률Personal Products 산업 성장률3.77%매출 성장률19.85%자기자본이익률42.30%순이익률21.00%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • Mar 20Full year 2025 earnings released: EPS: ₩2,414 (vs ₩1,036 in FY 2024)Full year 2025 results: EPS: ₩2,414 (up from ₩1,036 in FY 2024). Revenue: ₩78.2b (up 57% from FY 2024). Net income: ₩18.9b (up 150% from FY 2024). Profit margin: 24% (up from 15% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 77% per year, which means it is significantly lagging earnings growth.분석 기사 • Mar 25Genic's (KOSDAQ:123330) Earnings Aren't As Good As They AppearEven though Genic Co., Ltd. ( KOSDAQ:123330 ) posted strong earnings recently, the stock hasn't reacted in a large way...Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩1,036 (vs ₩643 loss in FY 2023)Full year 2024 results: EPS: ₩1,036 (up from ₩643 loss in FY 2023). Revenue: ₩49.9b (up 78% from FY 2023). Net income: ₩7.56b (up ₩12.0b from FY 2023). Profit margin: 15% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 61% per year whereas the company’s share price has increased by 60% per year.Reported Earnings • May 18First quarter 2022 earnings released: ₩342 loss per share (vs ₩46.00 profit in 1Q 2021)First quarter 2022 results: ₩342 loss per share (down from ₩46.00 profit in 1Q 2021). Revenue: ₩7.81b (down 25% from 1Q 2021). Net loss: ₩2.35b (down ₩2.66b from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • May 29Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩22,750, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 14x in the Personal Products industry in South Korea. Total returns to shareholders of 386% over the past three years.New Risk • May 23New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 41% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (41% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩23,250, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total returns to shareholders of 421% over the past three years.Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩28,750, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 18x in the Personal Products industry in South Korea. Total returns to shareholders of 523% over the past three years.Reported Earnings • Mar 20Full year 2025 earnings released: EPS: ₩2,414 (vs ₩1,036 in FY 2024)Full year 2025 results: EPS: ₩2,414 (up from ₩1,036 in FY 2024). Revenue: ₩78.2b (up 57% from FY 2024). Net income: ₩18.9b (up 150% from FY 2024). Profit margin: 24% (up from 15% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 77% per year, which means it is significantly lagging earnings growth.공시 • Mar 10Genic Co., Ltd., Annual General Meeting, Mar 24, 2026Genic Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 5, saneopdanji-ro 5-gil, seongdong-myeon, chungcheongnam-do, nonsan South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₩16,570, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 20x in the Personal Products industry in South Korea. Total returns to shareholders of 227% over the past three years.분석 기사 • Feb 06Genic Co., Ltd. (KOSDAQ:123330) Looks Just Right With A 42% Price JumpGenic Co., Ltd. ( KOSDAQ:123330 ) shareholders would be excited to see that the share price has had a great month...Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improves as stock rises 43%After last week's 43% share price gain to ₩23,350, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 350% over the past three years.New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). High level of non-cash earnings (25% accrual ratio).Valuation Update With 7 Day Price Move • Jan 22Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩18,980, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total returns to shareholders of 280% over the past three years.분석 기사 • Dec 04These 4 Measures Indicate That Genic (KOSDAQ:123330) Is Using Debt SafelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Valuation Update With 7 Day Price Move • Nov 21Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩17,900, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 282% over the past three years.New Risk • Nov 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.1b (US$92.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (37% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Market cap is less than US$100m (₩135.1b market cap, or US$92.2m).분석 기사 • Nov 03Under The Bonnet, Genic's (KOSDAQ:123330) Returns Look ImpressiveIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩23,000, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 20x in the Personal Products industry in South Korea. Total returns to shareholders of 469% over the past three years.Valuation Update With 7 Day Price Move • Oct 14Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩21,200, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 440% over the past three years.Buy Or Sell Opportunity • Aug 12Now 25% undervaluedOver the last 90 days, the stock has risen 20% to ₩31,250. The fair value is estimated to be ₩41,431, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable.분석 기사 • Jul 15Does Genic (KOSDAQ:123330) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Jun 16A Look At The Fair Value Of Genic Co., Ltd. (KOSDAQ:123330)Key Insights Genic's estimated fair value is ₩42,934 based on 2 Stage Free Cash Flow to Equity Genic's ₩41,750 share...Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩41,600, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 18x in the Personal Products industry in South Korea. Total returns to shareholders of 857% over the past three years.분석 기사 • May 26After Leaping 37% Genic Co., Ltd. (KOSDAQ:123330) Shares Are Not Flying Under The RadarGenic Co., Ltd. ( KOSDAQ:123330 ) shares have had a really impressive month, gaining 37% after a shaky period...Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩31,750, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 16x in the Personal Products industry in South Korea. Total returns to shareholders of 477% over the past three years.분석 기사 • May 23Genic (KOSDAQ:123330) Is Very Good At Capital AllocationIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...분석 기사 • Apr 09Risks Still Elevated At These Prices As Genic Co., Ltd. (KOSDAQ:123330) Shares Dive 25%To the annoyance of some shareholders, Genic Co., Ltd. ( KOSDAQ:123330 ) shares are down a considerable 25% in the last...Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩17,800, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 14x in the Personal Products industry in South Korea. Total returns to shareholders of 199% over the past three years.New Risk • Apr 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩147.1b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₩147.1b market cap, or US$99.9m).분석 기사 • Mar 25Genic's (KOSDAQ:123330) Earnings Aren't As Good As They AppearEven though Genic Co., Ltd. ( KOSDAQ:123330 ) posted strong earnings recently, the stock hasn't reacted in a large way...Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩1,036 (vs ₩643 loss in FY 2023)Full year 2024 results: EPS: ₩1,036 (up from ₩643 loss in FY 2023). Revenue: ₩49.9b (up 78% from FY 2023). Net income: ₩7.56b (up ₩12.0b from FY 2023). Profit margin: 15% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 61% per year whereas the company’s share price has increased by 60% per year.공시 • Mar 12Genic Co., Ltd., Annual General Meeting, Mar 26, 2025Genic Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 5, saneopdanji-ro 5-gil, seongdong-myeon, chungcheongnam-do, nonsan South Korea분석 기사 • Jan 23Genic (KOSDAQ:123330) Is Experiencing Growth In Returns On CapitalTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...분석 기사 • Dec 26Is Genic (KOSDAQ:123330) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Dec 09New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩134.2b market cap, or US$93.5m).New Risk • Dec 07New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩2.1b). Less than 3 years of financial data is available. Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩134.2b market cap, or US$94.3m).New Risk • Dec 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.2b free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩123.7b market cap, or US$88.1m).분석 기사 • Nov 29Genic Co., Ltd.'s (KOSDAQ:123330) Popularity With Investors Under Threat As Stock Sinks 30%The Genic Co., Ltd. ( KOSDAQ:123330 ) share price has softened a substantial 30% over the previous 30 days, handing...New Risk • Nov 14New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩133.3b (US$94.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩133.3b market cap, or US$94.9m).분석 기사 • Oct 10There's Reason For Concern Over Genic Co., Ltd.'s (KOSDAQ:123330) Massive 34% Price JumpDespite an already strong run, Genic Co., Ltd. ( KOSDAQ:123330 ) shares have been powering on, with a gain of 34% in...New Risk • Aug 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩42.2b market cap, or US$31.7m).New Risk • Jul 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩26.5b market cap, or US$19.2m).분석 기사 • Jul 27Genic Co., Ltd.'s (KOSDAQ:123330) Share Price Not Quite Adding UpThere wouldn't be many who think Genic Co., Ltd.'s ( KOSDAQ:123330 ) price-to-sales (or "P/S") ratio of 0.8x is worth a...분석 기사 • Mar 12Genic Co., Ltd.'s (KOSDAQ:123330) Shareholders Might Be Looking For ExitWith a median price-to-sales (or "P/S") ratio of close to 1x in the Personal Products industry in Korea, you could be...New Risk • Sep 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩2.3b free cash flow). Minor Risk Market cap is less than US$100m (₩28.3b market cap, or US$21.4m).Buying Opportunity • Dec 23Now 25% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be ₩5,922, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has declined by 73%.Buying Opportunity • Dec 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.0%. The fair value is estimated to be ₩6,492, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has declined by 73%.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • May 18First quarter 2022 earnings released: ₩342 loss per share (vs ₩46.00 profit in 1Q 2021)First quarter 2022 results: ₩342 loss per share (down from ₩46.00 profit in 1Q 2021). Revenue: ₩7.81b (down 25% from 1Q 2021). Net loss: ₩2.35b (down ₩2.66b from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.분석 기사 • Mar 19Genic (KOSDAQ:123330) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Mar 02New 90-day high: ₩5,660The company is up 53% from its price of ₩3,705 on 02 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 10.0% over the same period.Is New 90 Day High Low • Jan 27New 90-day high: ₩4,700The company is up 28% from its price of ₩3,685 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is up 18% over the same period.Is New 90 Day High Low • Jan 07New 90-day high: ₩3,995The company is up 2.0% from its price of ₩3,910 on 08 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 7.0% over the same period.분석 기사 • Dec 03We Think Genic (KOSDAQ:123330) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Sep 23New 90-day low: ₩3,720The company is down 6.0% from its price of ₩3,975 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 11% over the same period.매출 및 비용 세부 내역Genic가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A123330 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 2689,72718,8476,0901,60431 Dec 2578,19818,8875,6761,49830 Sep 2585,47218,3045,3221,30630 Jun 2577,04814,9185,3121,13931 Mar 2561,37311,7074,4471,04231 Dec 2449,9087,5634,44898130 Sep 2436,668-1444,42398030 Jun 2428,940-2,3694,2591,00931 Mar 2428,133-4,2295,6601,03531 Dec 2328,070-4,4115,9431,07830 Sep 2328,690-4,6955,7811,07530 Jun 2329,902-2,5564,6311,09631 Mar 2329,944-1,8053,8971,09631 Dec 2231,449-3,3404,2611,05930 Sep 2233,167-3,7217,0441,10330 Jun 2233,525-6,2498,6541,14131 Mar 2235,849-6,8609,4841,13331 Dec 2138,408-4,1999,4491,13430 Sep 2139,846-1,7648,0301,04830 Jun 2139,067-1,9477,36497431 Mar 2140,319-1186,45492031 Dec 2042,132317,08292930 Sep 2042,074-1,4656,9111,00030 Jun 2045,4283987,2261,01131 Mar 2044,5765297,5991,03131 Dec 1943,151-7127,10094930 Sep 1949,666-2,9118,0711,19130 Jun 1954,155-8,52611,59087931 Mar 1960,514-15,56214,9721,06231 Dec 1869,027-15,32317,2111,15230 Sep 1868,872-14,09218,2131,82230 Jun 1868,200-11,97518,5681,88631 Mar 1865,889-6,96518,4391,24931 Dec 1764,690-7,46718,9921,19630 Sep 1764,376-6,27716,274030 Jun 1768,865-2,86415,764031 Mar 1787,880-68619,47522131 Dec 1689,6681,22519,616030 Sep 1694,2293,65424,492-70330 Jun 1694,2803,26324,041-43931 Mar 1675,3732,70018,169-16231 Dec 1573,7062,92518,279030 Sep 1571,1724,47616,7711,01030 Jun 1567,4794,26516,8571,058양질의 수익: A123330의 비현금 수익 수준이 높습니다.이익 마진 증가: A123330의 현재 순 이익률 (21%)은 지난해 (19.1%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A123330는 지난 5년 동안 흑자전환하며 연평균 67.9%의 수익 성장을 기록했습니다.성장 가속화: 지난 1년간 A123330 의 수익 증가율(61%)은 5년 평균(연간 67.9%)보다 낮습니다.수익 대 산업: A123330의 지난 1년 수익 증가율(61%)은 Personal Products 업계의 10.8%를 상회했습니다.자기자본이익률높은 ROE: A123330의 자본 수익률(42.3%)은 뛰어남으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHousehold 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/12 10:22종가2026/06/12 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Genic Co., Ltd.는 6명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Eun Jung ParkDaishin Securities Co. Ltd.Na Young ParkDaiwa Securities Co. Ltd.Choi Soon-HoEugene Investment & Securities Co Ltd.3명의 분석가 더 보기
Reported Earnings • Mar 20Full year 2025 earnings released: EPS: ₩2,414 (vs ₩1,036 in FY 2024)Full year 2025 results: EPS: ₩2,414 (up from ₩1,036 in FY 2024). Revenue: ₩78.2b (up 57% from FY 2024). Net income: ₩18.9b (up 150% from FY 2024). Profit margin: 24% (up from 15% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 77% per year, which means it is significantly lagging earnings growth.
분석 기사 • Mar 25Genic's (KOSDAQ:123330) Earnings Aren't As Good As They AppearEven though Genic Co., Ltd. ( KOSDAQ:123330 ) posted strong earnings recently, the stock hasn't reacted in a large way...
Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩1,036 (vs ₩643 loss in FY 2023)Full year 2024 results: EPS: ₩1,036 (up from ₩643 loss in FY 2023). Revenue: ₩49.9b (up 78% from FY 2023). Net income: ₩7.56b (up ₩12.0b from FY 2023). Profit margin: 15% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 61% per year whereas the company’s share price has increased by 60% per year.
Reported Earnings • May 18First quarter 2022 earnings released: ₩342 loss per share (vs ₩46.00 profit in 1Q 2021)First quarter 2022 results: ₩342 loss per share (down from ₩46.00 profit in 1Q 2021). Revenue: ₩7.81b (down 25% from 1Q 2021). Net loss: ₩2.35b (down ₩2.66b from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • May 29Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩22,750, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 14x in the Personal Products industry in South Korea. Total returns to shareholders of 386% over the past three years.
New Risk • May 23New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 41% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (41% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).
Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩23,250, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total returns to shareholders of 421% over the past three years.
Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩28,750, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 18x in the Personal Products industry in South Korea. Total returns to shareholders of 523% over the past three years.
Reported Earnings • Mar 20Full year 2025 earnings released: EPS: ₩2,414 (vs ₩1,036 in FY 2024)Full year 2025 results: EPS: ₩2,414 (up from ₩1,036 in FY 2024). Revenue: ₩78.2b (up 57% from FY 2024). Net income: ₩18.9b (up 150% from FY 2024). Profit margin: 24% (up from 15% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 77% per year, which means it is significantly lagging earnings growth.
공시 • Mar 10Genic Co., Ltd., Annual General Meeting, Mar 24, 2026Genic Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 5, saneopdanji-ro 5-gil, seongdong-myeon, chungcheongnam-do, nonsan South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₩16,570, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 20x in the Personal Products industry in South Korea. Total returns to shareholders of 227% over the past three years.
분석 기사 • Feb 06Genic Co., Ltd. (KOSDAQ:123330) Looks Just Right With A 42% Price JumpGenic Co., Ltd. ( KOSDAQ:123330 ) shareholders would be excited to see that the share price has had a great month...
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improves as stock rises 43%After last week's 43% share price gain to ₩23,350, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 350% over the past three years.
New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). High level of non-cash earnings (25% accrual ratio).
Valuation Update With 7 Day Price Move • Jan 22Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩18,980, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total returns to shareholders of 280% over the past three years.
분석 기사 • Dec 04These 4 Measures Indicate That Genic (KOSDAQ:123330) Is Using Debt SafelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Valuation Update With 7 Day Price Move • Nov 21Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩17,900, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 282% over the past three years.
New Risk • Nov 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.1b (US$92.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (37% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Market cap is less than US$100m (₩135.1b market cap, or US$92.2m).
분석 기사 • Nov 03Under The Bonnet, Genic's (KOSDAQ:123330) Returns Look ImpressiveIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩23,000, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 20x in the Personal Products industry in South Korea. Total returns to shareholders of 469% over the past three years.
Valuation Update With 7 Day Price Move • Oct 14Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩21,200, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 440% over the past three years.
Buy Or Sell Opportunity • Aug 12Now 25% undervaluedOver the last 90 days, the stock has risen 20% to ₩31,250. The fair value is estimated to be ₩41,431, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable.
분석 기사 • Jul 15Does Genic (KOSDAQ:123330) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
분석 기사 • Jun 16A Look At The Fair Value Of Genic Co., Ltd. (KOSDAQ:123330)Key Insights Genic's estimated fair value is ₩42,934 based on 2 Stage Free Cash Flow to Equity Genic's ₩41,750 share...
Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩41,600, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 18x in the Personal Products industry in South Korea. Total returns to shareholders of 857% over the past three years.
분석 기사 • May 26After Leaping 37% Genic Co., Ltd. (KOSDAQ:123330) Shares Are Not Flying Under The RadarGenic Co., Ltd. ( KOSDAQ:123330 ) shares have had a really impressive month, gaining 37% after a shaky period...
Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩31,750, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 16x in the Personal Products industry in South Korea. Total returns to shareholders of 477% over the past three years.
분석 기사 • May 23Genic (KOSDAQ:123330) Is Very Good At Capital AllocationIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
분석 기사 • Apr 09Risks Still Elevated At These Prices As Genic Co., Ltd. (KOSDAQ:123330) Shares Dive 25%To the annoyance of some shareholders, Genic Co., Ltd. ( KOSDAQ:123330 ) shares are down a considerable 25% in the last...
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩17,800, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 14x in the Personal Products industry in South Korea. Total returns to shareholders of 199% over the past three years.
New Risk • Apr 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩147.1b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₩147.1b market cap, or US$99.9m).
분석 기사 • Mar 25Genic's (KOSDAQ:123330) Earnings Aren't As Good As They AppearEven though Genic Co., Ltd. ( KOSDAQ:123330 ) posted strong earnings recently, the stock hasn't reacted in a large way...
Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩1,036 (vs ₩643 loss in FY 2023)Full year 2024 results: EPS: ₩1,036 (up from ₩643 loss in FY 2023). Revenue: ₩49.9b (up 78% from FY 2023). Net income: ₩7.56b (up ₩12.0b from FY 2023). Profit margin: 15% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 61% per year whereas the company’s share price has increased by 60% per year.
공시 • Mar 12Genic Co., Ltd., Annual General Meeting, Mar 26, 2025Genic Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 5, saneopdanji-ro 5-gil, seongdong-myeon, chungcheongnam-do, nonsan South Korea
분석 기사 • Jan 23Genic (KOSDAQ:123330) Is Experiencing Growth In Returns On CapitalTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
분석 기사 • Dec 26Is Genic (KOSDAQ:123330) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Dec 09New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩134.2b market cap, or US$93.5m).
New Risk • Dec 07New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩2.1b). Less than 3 years of financial data is available. Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩134.2b market cap, or US$94.3m).
New Risk • Dec 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.2b free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩123.7b market cap, or US$88.1m).
분석 기사 • Nov 29Genic Co., Ltd.'s (KOSDAQ:123330) Popularity With Investors Under Threat As Stock Sinks 30%The Genic Co., Ltd. ( KOSDAQ:123330 ) share price has softened a substantial 30% over the previous 30 days, handing...
New Risk • Nov 14New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩133.3b (US$94.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩133.3b market cap, or US$94.9m).
분석 기사 • Oct 10There's Reason For Concern Over Genic Co., Ltd.'s (KOSDAQ:123330) Massive 34% Price JumpDespite an already strong run, Genic Co., Ltd. ( KOSDAQ:123330 ) shares have been powering on, with a gain of 34% in...
New Risk • Aug 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩42.2b market cap, or US$31.7m).
New Risk • Jul 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩26.5b market cap, or US$19.2m).
분석 기사 • Jul 27Genic Co., Ltd.'s (KOSDAQ:123330) Share Price Not Quite Adding UpThere wouldn't be many who think Genic Co., Ltd.'s ( KOSDAQ:123330 ) price-to-sales (or "P/S") ratio of 0.8x is worth a...
분석 기사 • Mar 12Genic Co., Ltd.'s (KOSDAQ:123330) Shareholders Might Be Looking For ExitWith a median price-to-sales (or "P/S") ratio of close to 1x in the Personal Products industry in Korea, you could be...
New Risk • Sep 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩2.3b free cash flow). Minor Risk Market cap is less than US$100m (₩28.3b market cap, or US$21.4m).
Buying Opportunity • Dec 23Now 25% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be ₩5,922, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has declined by 73%.
Buying Opportunity • Dec 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.0%. The fair value is estimated to be ₩6,492, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has declined by 73%.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • May 18First quarter 2022 earnings released: ₩342 loss per share (vs ₩46.00 profit in 1Q 2021)First quarter 2022 results: ₩342 loss per share (down from ₩46.00 profit in 1Q 2021). Revenue: ₩7.81b (down 25% from 1Q 2021). Net loss: ₩2.35b (down ₩2.66b from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
분석 기사 • Mar 19Genic (KOSDAQ:123330) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Mar 02New 90-day high: ₩5,660The company is up 53% from its price of ₩3,705 on 02 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Jan 27New 90-day high: ₩4,700The company is up 28% from its price of ₩3,685 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is up 18% over the same period.
Is New 90 Day High Low • Jan 07New 90-day high: ₩3,995The company is up 2.0% from its price of ₩3,910 on 08 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 7.0% over the same period.
분석 기사 • Dec 03We Think Genic (KOSDAQ:123330) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Sep 23New 90-day low: ₩3,720The company is down 6.0% from its price of ₩3,975 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 11% over the same period.